Newsletter | May 18, 2021

05.18.21 -- Scientists Design New Drug Compound To Stop Malaria In Its Tracks

Industry Insights
A Stepwise Approach To CMC Planning For A Biologics License Application

Lonza understands the challenges of designing a CMC strategy and has developed a structured and stepwise approach to planning that is tailored to our customers’ product, process, timelines, and risk tolerance.

Immuno-Oncology In Vitro Assays

Targeting immune checkpoints such as the PD-1 PD-L1 pathway has proven in recent years to be an effective treatment approach resulting in a range of approved mAbs that bind PD-1 or its ligand PD-L1. In this application note, we discuss our recently developed assay format to characterize checkpoint inhibitor mAbs, specifically discussing those that target the PD-1 PD-L1 pathway.

Bench To Bedside And FDA Submission Strategies For Cell And Gene Therapies

Cell therapies have the potential to transform global healthcare by providing curative therapies for once incurable diseases, but there are major challenges to their widespread adoption. Industry experts share their experiences and discuss emerging trends to accelerate life-saving therapies from the bench to the bedside.

Most Popular News
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.